R
38.41
-1.62 (-4.05%)
| Previous Close | 40.03 |
| Open | 40.17 |
| Volume | 2,917,969 |
| Avg. Volume (3M) | 1,991,650 |
| Market Cap | 7,154,553,856 |
| Price / Sales | 9.04 |
| Price / Book | 3.59 |
| 52 Weeks Range | |
| Earnings Date | 5 Aug 2025 - 11 Aug 2025 |
| Diluted EPS (TTM) | -4.01 |
| Total Debt/Equity (MRQ) | 6.46% |
| Current Ratio (MRQ) | 13.46 |
| Operating Cash Flow (TTM) | -591.31 M |
| Levered Free Cash Flow (TTM) | -349.13 M |
| Return on Assets (TTM) | -23.09% |
| Return on Equity (TTM) | -36.68% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Revolution Medicines, Inc. | Bearish | Bullish |
AIStockmoo Score
0.8
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | 0.75 |
|
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 1.99% |
| % Held by Institutions | 105.97% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Baker Bros. Advisors Lp | 31 Mar 2025 | 7,936,972 |
| Paradigm Biocapital Advisors Lp | 31 Mar 2025 | 6,178,111 |
| Bellevue Group Ag | 31 Mar 2025 | 4,374,300 |
| Boxer Capital, Llc | 30 Sep 2024 | 4,279,464 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 80.00 (Guggenheim, 108.28%) | Buy |
| Median | 69.50 (80.94%) | |
| Low | 57.00 (Needham, 48.40%) | Buy |
| Average | 69.17 (80.08%) | |
| Total | 6 Buy | |
| Avg. Price @ Call | 39.24 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Guggenheim | 25 Jun 2025 | 80.00 (108.28%) | Buy | 38.91 |
| 08 May 2025 | 80.00 (108.28%) | Buy | 41.91 | |
| Needham | 24 Jun 2025 | 57.00 (48.40%) | Buy | 40.03 |
| 08 May 2025 | 57.00 (48.40%) | Buy | 41.91 | |
| HC Wainwright & Co. | 14 May 2025 | 72.00 (87.45%) | Buy | 39.48 |
| Oppenheimer | 08 May 2025 | 75.00 (95.26%) | Buy | 41.91 |
| Wedbush | 28 Apr 2025 | 67.00 (74.43%) | Buy | 41.47 |
| Stifel | 01 Apr 2025 | 64.00 (66.62%) | Buy | 33.62 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |